12 results
The primary objective of the study is to demonstrate the antitumor activity of LDK378.
The primary objective is to evaluate the antitumor activity of ceritinib in patients with ALK-positive NSCLC metastatic to the brain and/or toleptomeninges based on whole body overall response rate (ORR), defined as the proportion of patients with a…
The study objective is to assess the safety and efficacy of the Permanent Polymer Zotarolimus-Eluting Stent Resolute Integrity* to the Polymer Free Amphilimus-Eluting Stent Cre8* compared in an all-comer patient population. 1 month of dual…
Primary: To assess the steady-state PK of 450 mg or 600 mg ceritinib taken daily with a low-fat meal as compared with that of 750 mg ceritinib taken daily in the fasted state in patients with metastatic ALK-positive NSCLC.Secondary: Overall response…
The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy.The key secondary objective is to compare Overall Survival (OS) in patients treated with LDK378 versus reference chemotherapy (pemetrexed or docetaxel…
Primary: 1. To determine the MTD and/or RDE of the combination ceritinib and nivolumab. 2. To assess the preliminary antitumor activity of the combination.Secondary: 1: To assess the safety profile of the ceritinib and nivolumab combination. 2: To…
The objective is to compare the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).
To evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control (TtC) regimen for the treatment of patients with neovascular age-related macular degeneration (nAMD) with the objective to evaluate the potential to reduce treatment…
In this study we want to find out how safe and effective is the new product brolucizumab. Brolucizumab is administered in this study to subjects with decreased sight due to diabetes macular edema. The effects of brolucizumab are compared with those…
To evaluate the efficacy and safety of brolucizumab in the treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) and its potential to reduce the treatment burden for patients.
The purpose of this study is to evaluate the efficacy and safety of brolucizumab used in a Treat- to-Control (TtC) regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular…
The primary objective is to compare the antitumor activity of LDK378 versus reference chemotherapy